GnRH2 antagonists stimulated loss of mitochondrial membrane potential and apoptosis in breast cancer cells via p38 MAPK and c-Jun N-terminal kinase (JNK) pathways, culminating in activation of the pro-apoptotic protein, BAX (47). Here, GNRH2 is linked to breast cancer.